What is Vaso Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Vaso's interest expense for the
three
months ended in Mar. 2024 was $ -0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.03 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Vaso's Operating Income for the
three
months ended in Mar. 2024 was $ -1.47 Mil. Vaso's Interest Expense for the
three
months ended in Mar. 2024 was $ -0.00 Mil.
Vaso did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Vaso Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaso (OTCPK:VASO) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Vaso's Interest Expense for the
three
months ended in Mar. 2024 was $-0.00 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-1.47 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $0.95 Mil.
Vaso's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| Vaso did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Vaso Corporation has enough cash to cover all of its debt. Its financial situation is stable.
Vaso (VASO) Business Description
Traded in Other Exchanges
N/A
Address
137 Commercial Street, Unit 200, Plainview, NY, USA, 11803
Vaso Corporation is a medical technology company. It provides diverse product and service categories, including noninvasive monitoring and therapeutic devices, diagnostic imaging equipment, and information technology for enterprises and clinical customers. The company currently operates in three distinct business units namely IT; Professional sales and Equipment. It generates maximum revenue from the IT segment. IT segment focuses on healthcare IT and managed network technology services.
Executives
| Leon Dembo |
director |
137 COMMERCIAL STREET, SUITE 200, PLAINVIEW NY 11803 |
| Janey Moen |
director |
137 COMMERCIAL STREET, SUITE 200, PLAINVIEW NY 11803 |
| Jun Ma |
director |
C/O VASOMEDICAL, INC., 180 LINDEN AVENUE, WESTBURY NY 11590 |
| Edgar Rios |
director |
1650 TYSONS BOULEVARD, SUITE 900, MCLEAN VA 22102 |
| Michael Beecher |
officer: Chief Financial Officer |
C/O DIRECT INSITE CORP, 80 ORVILLE DRIVE, BOHEMIA NY 11716 |
| Joshua Markowitz |
director |
3131 PRINCETON PIKE, BLDG. 3D, SUITE 200, LAWRENCEVILLE NJ 08648 |
| Jonathan P Newton |
officer: Vice Pres Finance & Controller |
152 RICHMOND AVENUE, AMITYVILLE NY 11701 |
| Peter C Castle |
director |
C/O NETWOLVES CORP, 4002 EISENHOWER BLVD, TEMPA FL 33634 |
| David H Lieberman |
director |
3061 INDUSTRY DR, LANCASTER PA 17603 |
| Behnam Movaseghi |
director |
C/O KERNS MANUFACTURING CORPORATION, 37-14 29TH STREET, LONG ISLAND CITY NY 11101 |
| Nelson Randall Hill |
officer: Senior Vice President |
3880 EAST COUNTY HIGHWAY 30A, UNIT 201, SANTA ROSA BEACH FL 24159 |
| William Edward Dempsey |
director |
52 PARK AVENUE, SANDYMOUNT L2 DUBLIN 4 |
| David Tarachand Singh |
officer: Chief Financial Officer |
C/O VASOMEDICAL, INC., 180 LINDEN AVENUE, WESTBURY NY 11590 |
| Joseph Giacalone |
director |
|
| Derek Enlander |
director |
88C UNION AVENUE, CENTER MORICHES NY 11934 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VASO has been successfully added to your 